NJ-DEALCLOUD
9.11.2020 11:02:12 CET | Business Wire | Press release
DealCloud (an Intapp company), a leading provider of deal, relationship and firm management solutions for capital markets firms, today released the Fall 2020 edition of its Dealmaker Pulse Survey, which indicates that private investors have moved past pandemic concerns regarding impact on current investments and are now concentrating on sourcing and closing new deals. In addition, a surprising number of firms raising new funds expect to meet or exceed their targets, despite existing dry powder.
“In the six months since our last survey, the focus has shifted from portfolio concerns to dealmaking,” said Ben Harrison, co-founder and president of DealCloud. “Investors expect founder-owned businesses to see significant deal activity, though private equity firms of all sizes recognize that finding quality assets at fair valuations will be a challenge with increased competition.”
The survey also revealed that fundraising may be returning to pre-pandemic levels. Only 12% of investors postponed or suspended fundraising plans, and a mere 6% lowered the target for their next fund. Meanwhile, an impressive 26% said their next fund will actually be larger than originally anticipated.
Other findings from the survey include:
- New platforms are the focus: 70% of investors said new platform investments are their primary focus over the next six months, compared to 35% six months ago
- Fewer investors expect valuations to decline further: only 35% of respondents said they expect valuations to decline, down from 93% in April
- The pandemic continues to impact the work environment: 47% of private equity firms have plans to return to the office, and only 40% have plans to resume business development travel, as technology-driven operations are seen by many as a bare minimum to remain competitive and cultivate key relationships
- For some, dealmaking evaporated: 30% of investors said their firm did not close a deal (platform or add-on) since March
“Clearly, investors are eager to deploy dry powder, but questions remain about who is able to close deals in this environment,” said Chris Gaffney, co-founder and managing partner of Great Hill Partners, a leading growth-oriented private equity firm. “Many firms are finding ways to close deals even as business development teams remain grounded, suggesting that the relationship cultivation that has traditionally taken place face-to-face has become increasingly reliant on technology over the past six months.”
DealCloud’s Dealmaker Pulse Fall 2020 Survey polled dealmakers to gain key insights into how capital markets firms are dealing with the effects of the global pandemic and thinking about opportunities for the fourth quarter, next year and beyond. The online survey was conducted via DealCloud Dispatch , the platform’s integrated marketing solution, amid the COVID-19 crisis from Sept. 21 to Oct. 5, 2020.
DealCloud will host a webinar to provide more color on the results of the DealCloud Dealmaker Pulse Fall 2020 Survey:
-
Dealmaker Pulse: Key Findings for Capital Markets Firms to Take into 2021
Thursday, Nov. 11, 2020 at 11:00am EST
Register here: https://dealcloud.com/event/dealcloud-dealmaker-pulse-key-findings-for-capital-markets-firms-to-take-into-2021/
To see the full results of the DealCloud Dealmaker Pulse Fall 2020 Survey, visit dealcloud.com/pulse .
About DealCloud
DealCloud, an Intapp company , provides a single-source deal, relationship, and firm management platform to enable more than 900 clients to power their dealmaking process from strategy to origination to execution. We offer fully configurable solutions purpose-built for the complex relationships and structures of private equity and growth capital firms, investment banks, private and publicly traded companies, debt capital providers, and other investors. For more information, visit dealcloud.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005198/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
